vs
Side-by-side financial comparison of DNA X, Inc. (SONM) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $13.7M, roughly 1.2× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -29.3%, a 105.0% gap on every dollar of revenue.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
SONM vs XLO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.2M | $13.7M |
| Net Profit | $-4.8M | $10.4M |
| Gross Margin | 11.2% | — |
| Operating Margin | -24.5% | -86.5% |
| Net Margin | -29.3% | 75.7% |
| Revenue YoY | 7.9% | — |
| Net Profit YoY | -89.2% | 179.1% |
| EPS (diluted) | $-4.83 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.7M | ||
| Q3 25 | $16.2M | $19.1M | ||
| Q2 25 | $11.2M | $8.1M | ||
| Q1 25 | $16.7M | $2.9M | ||
| Q4 24 | $15.3M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $11.5M | — | ||
| Q1 24 | $9.1M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | $-4.8M | $-16.3M | ||
| Q2 25 | $-7.5M | $-15.8M | ||
| Q1 25 | $458.0K | $-13.3M | ||
| Q4 24 | $-21.6M | — | ||
| Q3 24 | $-2.5M | — | ||
| Q2 24 | $-6.6M | — | ||
| Q1 24 | $-2.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | 7.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 28.2% | — | ||
| Q2 24 | 25.8% | — | ||
| Q1 24 | 31.8% | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | -24.5% | -10.1% | ||
| Q2 25 | -60.2% | -177.7% | ||
| Q1 25 | 3.9% | -472.7% | ||
| Q4 24 | 55.3% | — | ||
| Q3 24 | -15.8% | — | ||
| Q2 24 | -56.2% | — | ||
| Q1 24 | -29.5% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | -29.3% | -85.4% | ||
| Q2 25 | -66.8% | -196.0% | ||
| Q1 25 | 2.7% | -452.7% | ||
| Q4 24 | -141.6% | — | ||
| Q3 24 | -16.7% | — | ||
| Q2 24 | -57.5% | — | ||
| Q1 24 | -31.9% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | $-4.83 | $-0.11 | ||
| Q2 25 | $-0.79 | $-0.16 | ||
| Q1 25 | $0.08 | $-0.18 | ||
| Q4 24 | $-116.99 | — | ||
| Q3 24 | $-9.32 | — | ||
| Q2 24 | $-1.41 | — | ||
| Q1 24 | $-0.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $137.5M |
| Total DebtLower is stronger | $5.1M | — |
| Stockholders' EquityBook value | $-701.0K | $35.3M |
| Total Assets | $40.2M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $2.1M | $103.8M | ||
| Q2 25 | $2.0M | $121.6M | ||
| Q1 25 | $2.1M | $89.1M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $9.1M | — | ||
| Q2 24 | $9.6M | — | ||
| Q1 24 | $9.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $35.3M | ||
| Q3 25 | $-701.0K | $-8.1M | ||
| Q2 25 | $-1.3M | $7.1M | ||
| Q1 25 | $-1.1M | $10.7M | ||
| Q4 24 | $-5.7M | — | ||
| Q3 24 | $15.3M | — | ||
| Q2 24 | $17.5M | — | ||
| Q1 24 | $19.8M | — |
| Q4 25 | — | $154.7M | ||
| Q3 25 | $40.2M | $133.7M | ||
| Q2 25 | $36.1M | $133.8M | ||
| Q1 25 | $36.0M | $103.7M | ||
| Q4 24 | $39.7M | — | ||
| Q3 24 | $49.1M | — | ||
| Q2 24 | $45.9M | — | ||
| Q1 24 | $42.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.0M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $-7.0M | $-17.5M | ||
| Q2 25 | $-4.9M | $-14.5M | ||
| Q1 25 | $-9.6M | $29.0M | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-417.0K | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-168.0K | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-554.0K | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-198.0K | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | -29.6% | — | ||
| Q3 24 | -3.7% | — | ||
| Q2 24 | -29.8% | — | ||
| Q1 24 | -2.2% | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -20.97× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
